Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. (SMTI) is a leading medical technology company that aims to revolutionize the wound care and skincare markets through innovative solutions. Founded in 1982 and headquartered in Fort Worth, Texas, Sanara MedTech focuses on developing and commercializing technologies that improve clinical outcomes for patients while simultaneously reducing healthcare costs.
The company operates through its subsidiary, Wound Care Innovations, LLC, and offers a range of collagen-based wound care products under the brand name CellerateRX. These products are marketed for treating various types of wounds, including pressure ulcers, diabetic ulcers, surgical wounds, and burns. Available in both gel and powder forms, CellerateRX is designed to serve healthcare providers such as physicians, clinics, and hospitals.
Sanara MedTech's portfolio extends beyond surgical wound care, encompassing a comprehensive suite of chronic wound care products. The company's notable offerings include HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel. These products enable Sanara MedTech to deliver extensive wound and skincare solutions across all care settings, from acute to post-acute environments.
With a strategic focus on transformative technologies, Sanara MedTech holds worldwide licenses for certain proprietary technologies and processes. This positions the company at the forefront of advancing wound care treatment protocols. Recent achievements highlight the company's commitment to innovation and quality, making it a key player in the medical technology landscape.
Sanara MedTech also prioritizes transparent communication with its investors and stakeholders. For the latest updates and developments, the company's investor relations team is readily accessible, ensuring stakeholders are well-informed about performance metrics, ongoing projects, and future prospects.
Overall, Sanara MedTech Inc. continues to set the standard in wound care and skincare solutions, contributing significantly to the healthcare sector by enhancing patient care and operational efficacy.
Sanara MedTech Inc. (NASDAQ:SMTI) has successfully closed an underwritten public offering of 1,265,000 shares at $25.00 each, raising gross proceeds of $31.6 million. The offering included 165,000 additional shares exercised by underwriters. Proceeds will be used to expand the salesforce, develop product pipelines, and cover general corporate expenses. Previously, a shelf registration was filed with the SEC, and relevant prospectuses are available. Sanara aims to enhance patient outcomes through advanced wound care solutions.
Sanara MedTech Inc. has announced an underwritten public offering of 1,100,000 shares of common stock at a price of $25.00 per share, aiming for total gross proceeds of $27.5 million. The offering includes a 30-day option for underwriters to purchase an additional 165,000 shares. The offering is projected to close on February 17, 2021. Cantor Fitzgerald & Co. is the book-running manager for the offering, and the shares will be offered per an effective registration statement with the SEC.
Sanara MedTech Inc. (NASDAQ:SMTI) announced a proposed public offering of its common stock, with underwriters granted a 30-day option to purchase an additional 15% of shares. The offering is subject to market conditions and the final size and terms are yet to be determined. Cantor Fitzgerald & Co. is the book-running manager. The offering aims to improve patient outcomes through advanced wound and skin care products. Further details will be available via a prospectus filed with the SEC.
Sanara MedTech Inc. (NASDAQ: SMTI) reported preliminary results for Q4 and full year 2020, revealing Q4 revenue of $4.8 million, up 43% year-over-year from $3.4 million. Full-year revenue reached $15.6 million, a 32% increase from $11.8 million in 2019, driven by growth in sales force and distribution network expansion. Despite challenges posed by COVID-19, the company demonstrated resilience. As of December 31, 2020, cash and cash equivalents were approximately $0.5 million. Sanara also secured a $2.5 million revolving line of credit on January 15, 2021.
Sanara MedTech Inc. announced the appointment of Sara Ortwein to its Board of Directors, effective December 18, 2020. Ortwein, a former president of XTO Energy at ExxonMobil, brings 38 years of experience in engineering and management. Her addition is expected to enhance Sanara's strategic approach to wound and skin care products. Executive Chairman Ron Nixon emphasized her diversity of thought and executive-level expertise as valuable assets for the company. Sanara focuses on improving patient outcomes through advanced wound care and is expanding its telemedicine capabilities.
Sanara MedTech Inc. (NASDAQ: SMTI) reported a record revenue of $4.3 million for Q3 2020, marking a 48% increase year-over-year. The growth is attributed to the rebound in elective surgeries post-COVID restrictions. The company expanded its wound care strategy by forming United Wound and Skin Solutions LLC and investing in Direct Dermatology Inc. and Woundyne Medical LLC. Despite the revenue growth, Sanara incurred a net loss of $1.2 million for the quarter due to increased selling and administrative expenses.
Sanara MedTech Inc. (NASDAQ: SMTI) has announced an exclusive affiliation with Precision Healing, Inc. to commercialize advanced diagnostic systems aimed at enhancing chronic wound care outcomes. This partnership will utilize bedside diagnostic technology, including advanced imaging and molecular assays, to evaluate wound healing conditions. Sanara expects this innovative technology, which complements their existing wound care services and telemedicine platform, to be available commercially in 2021, contributing to their mission of improving patient outcomes through effective, evidence-based solutions.
Sanara MedTech Inc. (NASDAQ:SMTI) announced the launch of its BIAKŌS™ Antimicrobial Wound Gel and shared viral testing results for its BIAKŌS™ Skin and Wound Cleanser. The gel is designed for various wound types, promoting healing and disrupting biofilm microbes. Recent lab tests indicate that the cleanser effectively reduces SARS-CoV-2 viral loads, suggesting potential protective benefits. The Company aims to enhance patient outcomes with these products and is committed to expanding its offerings in wound care.
Sanara MedTech Inc. (OTCQB: SMTI) appointed Bob DeSutter to its Board of Directors, effective October 12, 2020. With 27 years of experience in healthcare investment banking, DeSutter brings valuable expertise to the Company. Executive Chairman Ron Nixon emphasized that DeSutter's insights will enhance the execution of Sanara's long-term wound and skin care strategy. Sanara focuses on patient outcomes through evidence-based solutions, marketing various products in the advanced wound care market. The appointment aims to strengthen the Company's leadership as it pursues growth in its six focus areas.
Sanara MedTech Inc (OTCQB: SMTI) has announced an exclusive affiliation with MGroup Integrated Physician Services, enhancing its telehealth capabilities in wound care. The partnership allows Sanara's subsidiary, UWSS, to provide management services, while MGroup will deliver clinical services. MGroup, a physician-led multispecialty group, aims to expand telehealth services to all 50 states by 2021. Dr. Chris Morrison, a seasoned healthcare executive, will lead telehealth efforts at UWSS, indicating a strategic move towards affordable virtual wound care solutions across the U.S.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
What is Sanara MedTech Inc. known for?
What products does Sanara MedTech offer?
Who are the primary customers for Sanara MedTech's products?
Where is Sanara MedTech Inc. headquartered?
When was Sanara MedTech Inc. founded?
How does Sanara MedTech contribute to healthcare cost reduction?
What forms does CellerateRX come in?
What conditions can CellerateRX treat?
How does Sanara MedTech ensure transparent communication with investors?
Who is the current Director of Investor Relations at Sanara MedTech?
